Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL).
Veltuzumab significantly reduces off-rates in human lymphoma cell lines, as well as increases complement-dependent cytotoxicity in 1 of 3 cell lines, but no other in vitro differences[1].Veltuzumab (0.001-10 μg/mL, 3 h) has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line[1].
Veltuzumab (i.v. or s.c.; 5, 20 and 60 μg; single) can control tumor growth or deplete circulating or sessile B cells at low doses in mouse models of intraperitoneal and subcutaneous doses[1]. Veltuzumab (i.p.; 0.05-35 μg) are significantly effective in vivo[1].
References:
[1]. David M Goldenberg, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood